ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid TissueBusiness Wire • Thursday
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire • 08/27/24
Adicet Reports Second Quarter 2024 Financial Results and Provides Business UpdatesBusiness Wire • 08/13/24
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell CarcinomaBusiness Wire • 07/08/24
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell CarcinomaBusiness Wire • 06/24/24
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus NephritisBusiness Wire • 06/05/24
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare ConferenceBusiness Wire • 05/29/24
Adicet Reports First Quarter 2024 Financial Results and Provides Business UpdatesBusiness Wire • 05/14/24
Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid CongressBusiness Wire • 05/14/24
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences ConferenceBusiness Wire • 05/07/24
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingBusiness Wire • 04/22/24
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual ConferenceBusiness Wire • 04/08/24
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 04/01/24
Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 03/22/24
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressBusiness Wire • 03/19/24